AstraZeneca to Market Junshi Bio’s PD-1 Cancer Drug in China - (Bloomberg via NewsPoints Desk)

  • AstraZeneca has inked a deal with Shanghai Junshi Biosciences to market the latter's anti-PD-1 cancer drug toripalimab for urothelial carcinoma across China, and for other cancer types in some areas, reported Bloomberg.

  • The two companies will also discuss commercial cooperation in emerging markets, according to the news source.

  • Bloomberg said this is the latest tie-up that sees a global pharmaceutical firm selling China's home-grown cancer therapies.

To read more NewsPoints articles, click here.